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C.  Influenza Activity on a Global Scale One important aspect of the influenza virus that has been addressed through collaborators of the Influenza Sequencing Project and others is the relationship of influenza on a global scale.  Influenza activity has long been associated with “cold-
weather” seasons in the temperate regions of the Northern and Southern Hemispheres.  
The influenza season begins in the temperate regions of the Northern Hemisphere; 
starting in November and ending in April, it peaks between December and February.  In 
the Southern Hemisphere, the peak months of influenza activity are June, July, and 
August.  The entire duration of the season is considered to last from May to October.  
During these ‘flu seasons’ influenza activity is greatest, although low levels continue 
throughout the year (Lofgren et al., 2007).  However, in the tropical regions around the 
equator, recent studies have shown significant levels of influenza activity year-round 


























































Positive Selection Type of Analysis REL –  No GARD  FEL –  No GARD  SLAC –   No GARD  REL – GARD  FEL ‐ GARD  SLAC ‐ GARD 
A.A. 
Y/N  p‐val  Y/N  p‐val  Y/N  p‐val  Y/N  Bayes  Y/N  p‐val  Y/N  p‐val 181  No  NA  No  NA  No  NA  Yes  621  No  NA  No  NA 262  No  NA  No  NA  No  NA  Yes  3920  Yes  0.046  No  NA 311  No  NA  No  NA  No  NA  Yes  569  No  0.090  No  NA 350  Yes  417.1  Yes  0.027  No  NA  Yes  2520  Yes  0.007  No  0.057 
 
Negative Selection Type of Analysis REL –  No GARD  FEL –  No GARD  SLAC –   No GARD  REL – GARD  FEL ‐ GARD  SLAC ‐ GARD 
A.A 
Y/N  p‐val  Y/N  p‐val  Y/N  p‐val  Y/N  Bayes  Y/N  p‐val  Y/N  p‐val 71  No  NA  Yes  0.049  No  NA  No  NA  No  NA  No  NA 79  No  NA  No  NA  No  NA  No  NA  Yes  0.027  No  NA 151  No  NA  Yes  0.010  Yes  0.037  No  NA  Yes  0.010  Yes  0.037 192  No  NA  No  0.060  No  NA  No  NA  Yes  0.015  Yes  0.038 252  No  NA  No  0.090  No  NA  No  NA  Yes  0.016  Yes  0.046 258  No  NA  Yes  0.022  No  0.090  No  NA  Yes  0.022  No  0.091 286  No  NA  No  0.091  No  NA  No  NA  Yes  0.017  Yes  0.046 357  No  NA  No  NA  No  NA  Yes  4006  Yes  0.001  Yes  0.005 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Positive Selection Type of Analysis SLAC ‐HyPhy  FEL ‐ HyPhy  REL ‐ Datamonkey  FEL ‐ Datamonkey  SLAC ‐Datamonkey 
  Codon   Select  p‐val  Select  p‐val  Select  Bayes  Select  p‐val  Select  p‐val 181 (165)  No  1.000  No  1.00  Yes  621  No  NA  No  NA 262 (264)  No  1.000  No  1.00  Yes  3920  Yes  0.046  No  NA 311 (295)  No  1.000  No  1.00  Yes  569  No  0.090  No  NA 350 (334)  No  1.000  Yes  0.027  Yes  2520  Yes  0.007  No  0.057 
Negative Selection Type of Analysis SLAC ‐HyPhy  FEL ‐ HyPhy  REL ‐Datamonkey  FEL ‐ Datamonkey  SLAC ‐Datamonkey 
 Codon 







































































Codon   Selected  p‐value  Selected  p‐value 
19 (3)  No  NA  Yes  0.030 
236 (220)  Yes  0.000  Yes  0.001 
  54 
Table 6­1. New York Hemagglutinin ­ Negative Selection This dataset does not contain any identical sequences.  Even with these identical sequences removed, this dataset was too large to perform any analyses on it through Datamonkey, including GARD.  Due to this, the results of the SLAC and FEL analyses performed using HyPhy, as shown below, do not take recombination into account.  The significance level applied for both methods is 0.05.  Some P‐values may be included for sites where an analysis did not detect selective pressure if one or more of the other analyses did. ‘Selected’ refers to whether the site was or was not identified as being selected.  




Negative Selection Type of Analysis SLAC ‐HyPhy  FEL – HyPhy  Codon  Select  p‐value  Select  p‐value 224  No  NA  Yes  0.014 228  No  NA  Yes  0.033 229  No  NA  Yes  0.022 234 (218)  No  NA  Yes  0.007 253  No  NA  Yes  0.022 255  No  NA  Yes  0.015 261  No  NA  Yes  0.034 266  No  NA  Yes  0.025 269  No  NA  Yes  0.026 271  No  NA  Yes  0.049 295  No  NA  Yes  0.041 310  No  NA  Yes  0.033 329  No  NA  Yes  0.033 335  No  NA  Yes  0.029 337 (321)  No  NA  Yes  0.006 339 (323)  No  NA  Yes  0.006 349 (333)  No  NA  Yes  0.000 351  No  NA  Yes  0.038 352 (7)  No  NA  Yes  0.032 353  No  NA  Yes  0.023 358  No  NA  Yes  0.023 367 (22)  No  NA  Yes  0.001 368  No  NA  Yes  0.023 373  No  NA  Yes  0.025 375  No  NA  Yes  0.027 376  No  NA  Yes  0.022 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Table 6­3. New York Hemagglutinin  ­ Negative Selection continued This dataset did not contain any identical sequences.  Even with these identical sequences removed, this dataset was too large to perform any analyses on it through Datamonkey, including GARD.  Due to this, the results of the SLAC and FEL analyses performed using HyPhy, as shown below, do not take recombination into account.  The significance level applied for both methods is 0.05. Some P‐values may be included for sites where an analysis did not detect selective pressure if one or more of the other analyses did. ‘Selected’ refers to whether the site was or was not identified as being selected.  
Negative Selection Type of Analysis SLAC ‐HyPhy  FEL – HyPhy  Codon  Select  p‐value  Select  p‐value 378 (33)   No  NA  Yes  0.001 386   No  NA  Yes  0.033 390  No  NA  Yes  0.011 396 (51)  No  NA  Yes  0.005 399 (54)  No  NA  Yes  0.000 404 (59)  No  NA  Yes  0.003 405  No  NA  Yes  0.028 406 (61)  No  NA  Yes  0.002 407  No  NA  Yes  0.016 409  No  NA  Yes  0.029 413  No  NA  Yes  0.016 419 (74)  No  NA  Yes  0.002 429  No  NA  Yes  0.031 432  No  NA  Yes  0.033 438  No  NA  Yes  0.047 441  No  NA  Yes  0.034 451  No  NA  Yes  0.030 496  No  NA  Yes  0.035 506  No  NA  Yes  0.024 509  No  NA  Yes  0.043 510  No  NA  Yes  0.012 515  No  NA  Yes  0.018 516 (171)  No  NA  Yes  0.000 519  No  NA  Yes  0.016 526 (181)  No  NA  Yes  0.003 531  No  NA  Yes  0.038 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Negative Selection Type of Analysis SLAC ‐HyPhy  FEL ‐ HyPhy  REL ‐ Datamonkey  FEL ‐ Datamonkey  SLAC ‐Datamonkey 
 Codon 





Negative Selection Type of Analysis SLAC ‐HyPhy  FEL ‐ HyPhy  REL ‐ Datamonkey  FEL ‐ Datamonkey  SLAC ‐Datamonkey 
 Codon 
















Select  p‐value  Select  p‐value 
30  No  0.425  Yes  0.022 
32  No  0.399  Yes  0.031 
33 (17)  No  0.404  Yes  0.023 
40 (24)  No  0.391  Yes  0.043 
46 (30)  No  0.391  Yes  0.042 
52 (36)  No  0.236  Yes  0.002 
72  No  0.404  Yes  0.023 
73  No  0.258  Yes  0.011 
95  No  0.391  Yes  0.025 
119  No  0.247  Yes  0.014 
125  No  0.399  Yes  0.028 
129  No  0.387  Yes  0.030 
131 (113)  No  0.097  Yes  0.001 
133 (115)  No  0.415  Yes  0.029 
149  No  0.336  Yes  0.021 
172  Yes  0.038  Yes  0.004 
177 (161)  No  0.393  Yes  0.028 
197  No  0.398  Yes  0.032 
203 (187)  No  0.207  Yes  0.003 
225  No  0.427  Yes  0.019 
231  No  0.563  Yes  0.014 
302  No  0.408  Yes  0.005 
315  No  0.399  Yes  0.027 
318  No  0.303  Yes  0.007 
321  No  0.425  Yes  0.021 












Select  p‐value  Select  p‐value 
335 (319)  No  0.398446  Yes  0.032 
339 (323)  No  0.438007  Yes  0.025 
351 (6)  No  0.31178  Yes  0.008 
367 (22)  No  0.392781  Yes  0.028 
374  No  0.37172  Yes  0.035 
383  No  0.381494  Yes  0.026 
395  No  0.398446  Yes  0.030 
404 (59)  No  0.299124  Yes  0.007 








Positive Selection Type of Analysis SLAC ‐ HyPhy  FEL ‐ HyPhy  REL ‐ Datamonkey  FEL ‐ Datamonkey Codon Position  Select  p‐value  Select  p‐value  Select  Bayes Factor  Select  p‐value 148  No  1.000  No  0.143  Yes  3505  No  NA 151  No  1.000  No  1.000  Yes  46150  No  NA 221  No  1.000  No  0.343  Yes  109  No  NA 385  No  1.000  No  1.00  Yes  110  No  NA 
 





























Positive Selection Type of Analysis SLAC ‐HyPhy  FEL ‐ HyPhy  REL ‐ Datamonkey  FEL ‐ Datamonkey  SLAC ‐Datamonkey   Codon   Select  p‐value  Select  p‐value  Select  Bayes Factor  Select  p‐value  Select  p‐value 267  No  1.000  Yes  0.042  No  NA  Yes  0.042  No  NA 
 












Codon   Select  p‐value  Select  p‐value  Select  p‐value 











Select  p‐value  Select  p‐value  Select  p‐value 
9  No  0.350  Yes  0.008  Yes  0.037 
12  No  0.354  Yes  0.041  No  NA 
20  No  0.769  Yes  0.021  No  0.061 
39  No  0.312  Yes  0.039  No  NA 
89  No  0.304  Yes  0.006  Yes  0.024 
128  No  1.000  Yes  0.027  No  0.084 
135  No  0.406  Yes  0.023  No  NA 
162  No  0.389  Yes  0.004  No  NA 
188  No  0.375  Yes  0.021  No  NA 
195  No  0.392  Yes  0.032  No  NA 
224  No  0.446  Yes  0.020  No  0.094 
225  No  0.361  Yes  0.040  No  NA 
244  No  0.360  Yes  0.007  Yes  0.038 
248  No  0.435  Yes  0.020  No  NA 
272  No  0.394  Yes  0.025  No  NA 
277  No  0.397  Yes  0.023  No  0.082 
278  No  0.243  Yes  0.010  Yes  0.021 
294  No  0.290  Yes  0.007  Yes  0.019 
302  No  0.284  Yes  0.007  Yes  0.006 
319  No  0.320  Yes  0.039  No  NA 
340  No  0.358  Yes  0.029  No  NA 
386  No  0.358  Yes  0.032  No  NA 
402  No  0.290  Yes  0.005  Yes  0.019 
403  No  0.319  Yes  0.006  Yes  0.029 
411  No  0.338  Yes  0.047  No  NA 
436  No  0.358  Yes  0.038  No  NA 
445  No  0.321  Yes  0.001  Yes  0.037 












Positive Selection Type of Analysis SLAC ‐HyPhy  FEL ‐ HyPhy  REL ‐ Datamonkey  FEL ‐ Datamonkey  SLAC ‐ Datamonkey 
  Codon   Select  p‐value  Select  p‐value  Select  Bayes Factor  Select  p‐value  Select  p‐value 215  No  1.000  No  0.204  Yes  144  No  NA  No  NA 
Negative Selection Type of Analysis SLAC ‐HyPhy  FEL ‐ HyPhy  REL ‐ Datamonkey  FEL ‐ Datamonkey  SLAC ‐ Datamonkey 
 Codon 





















































Positive Selection Type of Analysis SLAC ‐Datamonkey  FEL ‐ Datamonkey  REL ‐ Datamonkey  Codon   Selected  p‐value  Selected  p‐value  Selected  Bayes Factor 64  No  NA  No  NA  Yes  50.8566 174  No  NA  No  NA  Yes  1133.18 211  No  NA  No  NA  Yes  50.6761 218  No  NA  No  NA  Yes  1464.11 
 
































Positive Selection Type of Analysis SLAC ‐Datamonkey  FEL ‐ Datamonkey  REL ‐ Datamonkey   Codon   Selected  p‐value  Selected  p‐value  Selected  Bayes Factor 174  No  NA  No  NA  Yes  107.633 207  No  NA  No  NA  Yes  77.0256 208  No  NA  No  NA  Yes  261.38 211  No  NA  No  NA  Yes  150510 218  No  NA  No  NA  Yes  48484.2 219  No  NA  No  NA  Yes  4.97E+07 
 











Positive Selection Type of Analysis SLAC ‐Datamonkey  FEL ‐ Datamonkey  REL ‐ Datamonkey   Codon   Select  p‐value  Select  p‐value  Select  Bayes Factor 174  No  NA  No  NA  Yes  1.68E+06 211  No  NA  No  NA  Yes  1403.72 219  No  NA  No  NA  Yes  655.954 
 













Positive Selection Type of Analysis SLAC ‐Datamonkey  FEL ‐ Datamonkey  REL ‐ Datamonkey   Codon   Select  p‐value  Select  p‐value  Select  Bayes Factor NONE  No  NA  No  NA  No  NA 
 



















Positive Selection Type of Analysis SLAC ‐Datamonkey  FEL ‐ Datamonkey  REL ‐ Datamonkey   Codon   Selected  p‐value  Select  p‐value  Selected  Bayes Factor NONE  No  NA  No  NA  No  NA 
 













Positive Selection Type of Analysis SLAC ‐Datamonkey  FEL ‐ Datamonkey  REL ‐ Datamonkey   Codon   Select  p‐value  Select  p‐value  Select  Bayes Factor NONE  No  NA  No  NA  No  NA 
 










Positive Selection Type of Analysis SLAC ‐Datamonkey  FEL ‐ Datamonkey  REL ‐ Datamonkey   Codon   Select  p‐value  Select  p‐value  Select  Bayes Factor NONE  No  NA  No  NA  No  NA 
 












Positive Selection Type of Analysis SLAC ‐Datamonkey  FEL ‐ Datamonkey  REL ‐ Datamonkey   Codon   Select  p‐value  Select  p‐value  Select  Bayes Factor 16  No  NA  No  NA  Yes  212.317 
 






































































































































































12        0.08991 
19  0.0196497       
35  0.096504       
47  0.0494641       
48        0.0896485 
50  0.0952601       
61    0.0646573     
79  0.0952074       
95  0.0953262       
97  0.0953262      0.0896485 
98  0.094873       
119    0.0910465    0.0325286 
122  0.023946       
160  0.023946       
162  0.0946671       
165        0.0963047 
183  0.0616141       
198        0.0953837 
203    0.0461581     
206      0.0789996   
209    0.0743727     
229  0.0512126       
230        0.0536849 
234      0.079522   
245  0.0627187  0.06209     
249        0.0853757 
277      0.0616373   




































































































Australia Codon Position  New York  Denmark  Vietnam  Kentucky/ Virginia 
59      0.0970227   
















New York Codon Position  Vietnam  Denmark  Australia  Kentucky/ Virginia 
59  0.0598229       
99  0.0971141       
104  0.0946657       







Kentucky/Virginia Codon Position  Vietnam  Denmark  Australia  New York 




Vietnam Codon Position  New York  Denmark  Australia  Kentucky/ Virginia 
59  0.0598229  0.0957903     
99  0.0971141    0.0970227   
104  0.0946657    0.0954705   





































































13              0.0364       
19          0.0196           
47          0.0495           
95    0.0406                 
119  0.0325              0.0910     
122          0.0240           
162      0.0432               
173                  0.0405   
198    0.0493                 
203        0.0231    0.0226    0.0462     
235    0.0138                 
291    0.0168        0.0466         
325        0.0498             
329      0.0928        0.0897      0.0466 
330      0.0407        0.0157    0.0387  0.0472 
339        0.0512    0.0899    0.0337     
374  0.0455                   
383        0.0479             
395  0.0187                   
406  0.0272                   
466          0.0498           
492  0.0345        0.0345           
505          0.0250 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